The First Medicine to Prevent Chemotherapy-Related Nerve Damage in the Hands and Feet Is on the Way

Researchers in the Neuro-Oncology Department at Bellvitge University Hospital in Barcelona successfully tested a new molecule that may prevent peripheral neuropathy (nerve damage in the hands and feet) caused by chemotherapy, particularly in colon cancer. Medicines tested so far were not intended to prevent neuropathy, but offered limited benefit after the side effect developed (only duloxetinehad demonstrated benefit for these symptoms). With an entirely new mechanism, this molecule is a candidate for the first treatment against this neurological side effect, for which no effective treatment has yet been approved.
Colon and rectal (colorectal) cancer is the 3rd most common cancer worldwide in both women and men. Today, more than %70 of patients are diagnosed early (stages 1 – 3), and many receive preventive chemotherapy after surgery, the initial treatment, for 3-6 months (adjuvant). This preventive chemotherapy regimen is highly effective in reducing recurrence risk and is called FOLFOX . Its medicine oxaliplatin may cause peripheral neuropathy, particularly with long-term use (with 6 months of use, up to %50). Peripheral neuropathy is defined as tingling, numbness and pain in the hands and feet. Chemotherapy’s effectiveness and necessity in colon cancer mean we must partly accept this side effect.
- Related topic: Should preventive chemotherapy for colorectal cancer last 6 months or 3 months?
Dr. Jordi Bruna and his team developed a new molecule to prevent this side effect. The candidate medicine, code-named MR309, functions as a sigma-1 receptor antagonist . Antagonists are substances that prevent the receptors they bind from functioning (the best-known example is tamoxifen).
MR309’s effect on preventing chemotherapy-induced peripheral neuropathy was demonstrated in a phase-2 clinical trial , with results published in September 2017. This randomized, multicenter, double-blind, placebo-controlled study enrolled 124 patients with colon cancer. They were divided into 2 groups: one received, during every FOLFOX regimen for 5 days, a daily dose of 400 mg MR309, while the other received placebo (a product without active ingredient). Long-term severe neuropathy rates with MR309 were %3, while in the placebo group they were %18.
In conclusion, because colon cancer is among the most common cancers, chemotherapy-induced nerve damage in the hands and feet affects millions. Developing a treatment to prevent peripheral neuropathy is very promising because current treatments have limited benefit once it occurs. Researchers also noted the molecule’s potential use in other neuropathy types. We eagerly await MR309’s phase-3 clinical trial results and will share developments.
- Related topic: Diagnosis and treatment of chemotherapy-induced neuropathy (nerve damage)
Further reading: What is the Sigma-1 receptor (S1R)?
S1R is a transmembrane protein in the endoplasmic reticulum, particularly the mitochondria-associated endoplasmic reticulum membrane, capable of translocating to the plasma membrane. In the nervous system, S1Rs mediate regulation of processes including neuritogenesis, potassium channels, N-methyl-D-aspartate receptor activity and calcium homeostasis. S1Rs modulate nociception and attenuate intracellular signaling pathways associated with harmful stimuli and sensitization. Nociception encompasses the complex electrochemical events between tissue damage and pain perception. MR309 is the only molecule so far shown to inhibit S1R and tested in clinical trials for this purpose.
Sources
Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.
Neurotherapeutics. 2017 Sep.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.